Abaloparatide use increases the risk of osteosarcoma and osteosarcoma-related mortality.

The injection site should be monitored for reactions, and administration should be stopped if a reaction does occur. Blood pressure should also be monitored after injection to evaluate the patient for orthostatic hypotension.